secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004183
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm reports preliminary FY2022 revenue ~$157.7M, extends cash runway to late 2025
--------------------------------------------------------------------------------

- Preliminary FY2022 total revenue ~$157.7M; XPOVIO US net revenue ~$120.4M, up 22% YoY.
- Q4 2022 total revenue ~$34.2M; XPOVIO US net revenue ~$31.1M.
- Cash & investments ~$279.0M as of Dec 31, 2022, following $165M private placement; runway extended to late 2025.
- Initiated Phase 3 EC-042 for selinexor in TP53 wild-type endometrial cancer; partnership with Foundation Medicine for companion Dx.
- Planning to initiate Phase 3 MF study in 1H 2023; updated Phase 1 selinexor+ruxolitinib data in MF expected in 1H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523004183/0001193125-23-004183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000119312523004183/d435746d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer